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a b s t r a c t
Introduction and Objectives: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in children and it is more prevalent in Hispanic males. The gender differences can be explained by
body fat distribution, lifestyle, or sex hormone metabolism. We evaluated anthropometric and metabolic
differences by gender in children with and without NAFLD.
Methods: We included 194 participants (eutrophic, overweight, and individuals with obesity). The presence of NAFLD was determined using ultrasonography, and we evaluated the association between this
disease with metabolic and anthropometric variables by gender.
Results: The mean age was 10.64 ± 2.54 years. The frequency of NAFLD in boys was 24.51% and in girls
was 11.96% (OR = 2.39; 95%CI = 1.10–5.19; p = 0.025). For girls, NAFLD was signiﬁcantly associated with
triglycerides (p = 0.012), homeostatic model assessment of insulin resistance (HOMA-IR) (p = 0.048), and
the visceral adiposity index (VAI) (p = 0.024). The variables related to NAFLD in a gender-speciﬁc manner
were body mass index (BMI) (p = 0.001), waist circumference (WC) (p < 0.001), HDL cholesterol (p = 0.021),
alanine aminotransferase (ALT) (p < 0.001), and aspartate aminotransferase (AST) (p = 0.002).
Conclusions: In our study NAFLD is more frequent in boys, only ALT, and no other clinical or metabolic
variables, were associated with NAFLD in these patients. HOMA-IR, VAI, triglyceride levels, and ALT were
associated with NAFLD only in girls. The ALT cut-off points for the development of NAFLD in our study
were 28.5 U/L in females and 27.5 U/L in males. Our ﬁndings showed that NAFLD should be intentionally
screened in patients with obesity, particularly in boys.
© 2019 Fundación Clı́nica Médica Sur, A.C. Published by Elsevier España, S.L.U. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is deﬁned by the presence of steatosis in more than 5% of hepatocytes in patients with
no history of alcohol consumption, no pharmacological treatment,
and no congenital disease [1,2]. NAFLD is the most frequent type

∗ Corresponding author at: Department of Human Genetics, Hospital General de
México “Dr Eduardo Liceaga”, Dr. Balmis 148, Col. Doctores, Delegación, Cuauhtémoc, CP 06720, Ciudad de México, Mexico.
E-mail address: gngaribay@hotmail.com (G.N. Garibay-Nieto).

of liver disease in the pediatric population, with an overall prevalence of 7.6% and a cumulative prevalence of 34.2% in children with
obesity [3]. Epidemiological studies of NAFLD in Mexico show a
prevalence of 17.05% in asymptomatic adults and 12.6% in children
with a body mass index (BMI) >85th percentile (overweight and
obesity) [4,5].
Cross-sectional studies on humans and animal models have
reported a higher prevalence of NAFLD in the male gender. In the
pediatric population with obesity, the distribution by sex is 35.3%
in males and 21.8% in females [3]. Central obesity, insulin resistance, dyslipidemia, Hispanic ethnicity, and the genetic variants
COL13A1, ADIPOQ, SAMM50, and PNPLA3 in Mexican Americans

https://doi.org/10.1016/j.aohep.2019.04.012
1665-2681/© 2019 Fundación Clı́nica Médica Sur, A.C. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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and the Mexican-Mestizo population are the variables that are most
frequently associated with NAFLD [6–9].
Although a higher prevalence of NAFLD has been reported in
boys, gender-speciﬁc characteristics of this disorder have rarely
been explored. It has been proposed that the gender-speciﬁc differences observed in the prevalence of NAFLD may result from the
possible protective role of estrogens, which decrease the risk for
this disorder among females. Recent ﬁndings on the physiopathology of NAFLD, evaluated from a gender-speciﬁc perspective, have
indicated that lipid metabolism and body fat distribution may play
a relevant role [10,11].
Pediatric patients are not frequently screened for NAFLD, and
thus, it is rarely identiﬁed, primarily because of the complexity
of the diagnosis [2,12]. This study aimed to evaluate the genderspeciﬁc differences in the clinical and metabolic variables in a
pediatric population with NAFLD.
2. Methods
2.1. Study design
A cross-sectional comparative study was performed. Eutrophic,
overweight, and individuals with obesity and ranging in age from
6–18 years were consecutively included from January 2015 to
September 2016. Patients with overweight/obesity from the Childhood Obesity Clinic of the Hospital General de Mexico were invited
to participate, whereas eutrophic children were recruited from surrounding schools. All patients included in this study were born
and raised in Mexico City and the suburban area. The local ethics
committee approved the protocol.
The participants were classiﬁed into the following groups,
according to the Centers for Disease Control and Prevention guidelines: eutrophic (BMI <85th percentile); overweight (BMI ≥85th
and <95th percentile); and obesity (BMI ≥95th percentile).
Patients with obesity that had a genetic or endocrine origin;
those with a previously known liver disease, diabetes or other
endocrinopathies; patients receiving a pharmacological treatment
that was able to modify lipid or carbohydrate metabolism; and
those who reported alcohol consumption were excluded.
Informed consent and assent were obtained from the participants and their parent/legal guardian. All sensitive patient data
were protected in compliance with the Health Insurance Portability and Accountability Act (HIPAA). A complete medical record was
documented for each participant.
The NAFLD diagnosis was determined by a liver ultrasound that
was performed by an expert ultrasonographer.

2.2. Anthropometric and metabolic evaluation
The clinical variables assessed were age, gender, weight, height,
BMI, waist circumference (WC), and sexual development stage.
A mechanical scale and a stadiometer were used to evaluate
weight and height. The measuring location for WC was the midway
point between the last costal cartilage and the anterosuperior iliac
crest. Pediatricians and pediatric endocrinologists appraised the
sexual status, according to the Tanner scale [13,14]. Arterial blood
pressure was measured from the right brachial artery using a manual sphygmomanometer and special-sized pressure cuffs according
to the patient’s age, and the measurement was taken twice per
patient, with the patient in a sitting position.
We calculated the BMI according to Quetelet’s equation [15].
Additionally, using the homeostatic model assessment of insulin
resistance (HOMA-IR), we calculated the insulin resistance index
[16].
A gender-speciﬁc visceral adiposity index (VAI) was calculated
using a formula that was previously proposed by our group for

pediatric populations, as follows:
Female VAI = WC/(−0.018[BMI2 ] + 3.3[BMI] + 7.86)
× (Triglycerides/0.91) × (1.42/HDL); and

Male VAI = WC/(−0.023[BMI2 ] + 3.83[BMI] + 0.65)
× (Triglycerides/0.76) × (1.37/HDL).
Metabolic variables were evaluated by obtaining venous blood
after the patients had fasted for 12 h. Enzymatic methods were performed to measure glucose, aminotransferases, total cholesterol,
high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, and triglycerides, using available commercial
kits. Insulin was determined through chemiluminescence analysis.
Normal values were considered according to the North American
Society for Pediatric Gastroenterology, Hepatology and Nutrition
(NASPGHAN) and the Endocrine Society clinical practice guidelines
for NAFLD and pediatric obesity, respectively (alanine aminotransferase (ALT) <25 U/L in boys and <22 U/L for girls, HDL <40 mg/dL,
and triglycerides in patients 0–9 years <100 mg/dL and 10–19 years
<130 mg/dL) [17,18].
2.3. Ultrasonography
The NAFLD diagnosis was performed using a B mode ultrasound
and a 1–4 mHz curve transducer (Siemens Acuson S2000, Mountain
View, CA, USA), according a standardized protocol, by an expert
ultrasonographer who was blinded to the clinical and metabolic
conditions [19,20]. The kappa coefﬁcient for intra-observer concordance was 0.90. The steatosis condition was categorized as
present/not present, according to the hepatic tissue’s echogenicity,
in contrast to the adjunct right kidney’s parenchyma.
2.4. Statistical analyses
Descriptive and inferential statistics for numerical variables
were reported as the mean and standard deviation (SD), and the
percentages were used for categorical variables.
The inferential statistical analyses included a two-factor analysis of variance (ANOVA) for all anthropometric and metabolic
variables, considering the presence of NAFLD and gender as factor variables, and we ensured that the test assumptions were met.
The effect size was calculated using Cohen’s f and was considered to
be as follows: >0.10 small; >0.25 medium; and >0.40 large [21,22].
Chi-squared tests and Fisher’s exact test were used to assess
categorical variables. Binary logistic regression evaluated the
association between NAFLD and BMI-Pc, ALT, aspartate aminotransferase (AST), WC by gender, and triglycerides by sex [23].
The most relevant variables related to NAFLD were evaluated
using the receiver operating characteristics (ROC) curve analysis,
according to gender. The cut-off points, sensitivity, and speciﬁcity
were obtained for each variable [24,25].
All analyses were performed using the statistical software IBM
SPSS Statistics version 22.0 (IBM, Armonk, NY, USA). A p value of
<0.05 was considered to be statistically signiﬁcant.
3. Results
3.1. Descriptive statistics
A total of 194 patients (102 males and 92 females) were
recruited: 44 eutrophic, 38 overweight, and 112 with obesity. The
mean age of the participants was 10.64 ± 2.54 years.
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The overall NAFLD frequency in our study was 18.55%; it was
24.51% in boys and 11.96% in girls, which was signiﬁcantly different
(OR = 2.39; 95%CI = 1.10–5.19; p = 0.025).
In the obesity group, the frequency was 29.46%: 32.8% in males
and 24.4% in females (OR = 1.51; 95%CI = 0.65–3.54; p = 0.340). We
found that 91.7% of the patients with a NAFLD were obese.
The participants’ demographic and anthropometric characteristics (by gender) are shown in Table 1.
3.2. Inferential statistics
Differences in anthropometric and metabolic variables by gender and the presence of NAFLD were assessed using two-factor
ANOVAs.
We found statistically signiﬁcant differences between gender
and the presence of NAFLD for the following variables: triglycerides
(F(1,185) = 6.618, p = 0.012, f = 0.0895); insulin (F(1,174) = 6.197,
p = 0.021, f = 0.087); HOMA-IR (F(1,174) = 4.28, p = 0.048, f = 0.0895),
and VAI (F(1,185) = 5.47, p = 0.02, f = 0.0959). The combined effect
of the presence of NAFLD and gender was also evaluated for
all signiﬁcant ANOVAs. The mean triglyceride concentration in
males with and without NAFLD and in females with and without
NAFLD were 132.32 ± 68.14, 120.85 ± 68.08, 210.18 ± 73.26, and
126.38 ± 74.13 mg/dL, respectively. When comparing differences in
triglyceride concentrations among the male and female patients
with and without this disease, we found that the mean triglyceride concentration in female NAFLD patients was 77.86 mg/dL
higher than that in males. Similarly, in the group without NAFLD,
the triglyceride levels were higher in females compared to males,
with a mean difference of 5.53 mg/dL. The difference between the
differences was 70.993 (95%CI, 15.966–126.02, p = 0.012).
For insulin concentrations, the mean levels in males with and
without NAFLD and in females with and without this disorder
were 15.00 ± 5.69, 13.11 ± 6.75, 14.16 ± 12.08, and 14.92 ± 8.43
UI/L, respectively. In a mean comparison by gender and the
presence of NAFLD, male NAFLD patients had higher insulin concentrations compared to females, with a mean difference of 0.84
UI/L, whereas among patients without NAFLD, females had higher
insulin concentrations, with a mean difference of 1.81 UI/L. The difference between the differences was 7.357 (95%CI, 1.145–13.569,
p = 0.021).
The mean HOMA-IR levels in males with and without NAFLD and
in females with and without NAFLD were 3.24 ± 1.20, 2.56 ± 1.69,
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5.20 ± 2.70, and 3.04 ± 1.99, respectively. In a mean comparison by
gender and the presence of NAFLD, in patients with NAFLD, females
had a higher mean HOMA-IR level compared to males, with a mean
difference of 1.96 points. Similarly, in patients without NAFLD, the
HOMA-IR level was also higher in females than in males, with a
smaller mean difference of 0.48 points. The difference between the
differences was 1.471 (95%CI, 0.013–2.928, p = 0.048).
For VAI scores, the mean values in males with and without
NAFLD and in females with and without NAFLD were 2.87 ± 1.97,
2.57 ± 1.89, 4.30 ± 1.75, and 2.38 ± 1.66, respectively. In a mean
comparison by gender and the presence of NAFLD, in NAFLD
patients, the VAI scores were higher in females compared to males,
with a mean difference of 1.43 points. Similarly, among the participants without NAFLD, females had higher VAI scores than males,
with a mean difference of 0.19 points. The difference between the
differences was 1.62 (95%CI, 0.215–3.024, p = 0.024) (Table 1 and
Fig. 1).
For the variables that did not demonstrate signiﬁcant interactions in factorial ANOVAs, the main effects were evaluated. The
following signiﬁcant main effects from NAFLD were observed: for
BMI-Percentile (Pc) the mean was 97.48 ± 2.01 for patients with
NAFLD vs. 83.87 ± 22.52 for those without NAFLD (p = 0.001); for
WC, the mean was 86.82 ± 12.73 with NAFLD vs. 77.43 ± 13.47
without NAFLD (p < 0.001); for HDL cholesterol, the mean
was 37.53 ± 6.93 with NAFLD vs. 41.54 ± 10.21 without NAFLD
(p = 0.018); for ALT, the mean was 48.28 ± 21.98 with NAFLD vs.
22.22 ± 9.81 without NAFLD (p < 0.001); and for AST, the mean
was 36.14 ± 10.55 with NAFLD vs. 27.22 ± 6.58 without NAFLD
(p = 0.002; Table 1 and Fig. 1).
A binomial logistic regression was performed to ascertain the
effects of BMI percentile, ALT, WC by gender, and triglycerides by
gender on the likelihood that participants would have NAFLD. The
logistic regression model was statistically signiﬁcant (2 (6) = 79.47,
p < 0.0001). The model explained 54.9% (Nagelkerke’s R2 ) of the
variance in NAFLD and correctly classiﬁed 81.2% of the cases. The
sensitivity of the model was 79%, and speciﬁcity was 90%; the positive predictive value was 53%, and the negative predictive value
was 97%. The model was then internally validated using the ROC
curve. The AUC value was 0.922 (95%CI = 0.877–0.966, p < 0.0001).
The only statistically signiﬁcant variable was ALT (Table 2).
With the aim of evaluating the accuracy of the variables associated with NAFLD by gender, we performed receiver-operating
characteristics (ROC) curve discrimination. For female participants

Table 1
Clinical and metabolic variables associated to NAFLD by gender in Mexican children.
Variables

Age (years)
BMI (percentile)
SBP (mmHg)
DBP (mmHg)
WC (cm)
Glucose (mg/dL)
Triglycerides (mg/dL)
Total-C. (mg/dL)
HDL-C (mg/dL)
ALT (IU/L)
AST (IU/L)
Insulin (IU/L)
HOMA-IR
VAI

Male

Gender

NAFLD

Gender and NAFLD

NAFLD n = 25

No NAFLDn = 77

Female
NAFLD n = 11

No NAFLDn = 81

p

p

p

11.08 ± 2.04
97.33 ± 2.19
99.17 ± 8.66
63.75 ± 6.25
86.82 ± 12.73
88.00 ± 5.88
132.32 ± 68.14
158.64 ± 26.64
38.40 ± 6.72
49.0 ± 24.50
36.16 ± 11.41
15.00 ± 5.69
3.24 ± 1.20
2.87 ± 1.97

10.26 ± 2.47
85.85 ± 22.49
96.59 ± 8.92
62.03 ± 6.72
77.57 ± 13.66
88.38 ± 5.83
120.85 ± 68.08
163.62 ± 31.14
42.61 ± 12.76
24.49 ± 10.94
28.83 ± 7.10
13.11 ± 6.75
2.56 ± 1.69
2.57 ± 1.89

10.83 ± 3.27
97.82 ± 1.56
100.91 ± 9.44
64.09 ± 7.36
86.46 ± 14.51
86.73 ± 7.17
210.18 ± 73.26
171.27 ± 30.24
35.55 ± 7.30
46.64 ± 15.67
36.09 ± 8.80
14.16 ± 12.08
5.20 ± 2.70
4.30 ± 1.75

10.85 ± 2.64
81.72 ± 23.75
96.54 ± 8.83
61.91 ± 6.92
75.89 ± 11.89
86.23 ± 11.59
126.38 ± 74.13
154.86 ± 30.59
40.78 ± 8.54
22.50 ± 24.57
27.43 ± 16.66
14.92 ± 8.43
3.04 ± 1.99
2.38 ± 1.66

0.736
0.661
0.493
0.925
0.670
0.325
0.003*
0.747
0.247
0.173
0.768
0.001*
0.001*
0.083

0.423
0.001
0.083
0.171
<0.001
0.972
0.001*
0.342
0.021
<0.001**
0.002*
0.001*
<0.001*
0.002*

0.406
0.579
0.461
0.781
0.388
0.800
0.012
0.076
0.801
0.662
0.789
0.021
0.048
0.024

Values expressed as means ± standard deviation.
NAFLD: non-alcoholic fatty liver disease; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; WC: waist circumference; C: cholesterol; ALT:
alanine aminotransferase; AST: aspartate aminotransferase; HOMA-IR: homeostatic model assessment; VAI: visceral adiposity index.
Effect size (f) = *0.10–0.24; **0.25–0.39.
Bold values are p values < 0.05.
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SPB (mmHg)

BMI percentile
100.00

DBP (mmHg)

101

64.5

100

64.0

99

63.5

98

63.0

97

62.5

95.00

90.00

85.00

80.00

96

Control
WC (cm)

NAFLD

62.0

Control

NAFLD
Glucose (mg/dL)

Control
NAFLD
Triglycerides (mg/dL)

88.5

220

85.0

88.0

200

82.5

87.5

180

87.0

160

86.5

140

87.5

80.0

77.5

75.0
86.0

120

Control

Control
NAFLD
HDL-C (mg/dL)

NAFLD

Control

NAFLD

Insulin (IU/L)

ALT (IU/L)
50

24.00
42
22.00
40

40

20.00
30
18.00

38
16.00

20

14.00

36

10

12.00

Control

Control

NAFLD

NAFLD

Control

38

NAFLD
VAI

HOMA-IR
5.50

4.50

36
5.00
4.00
34
4.50
3.50

32
4.00
30

3.00

3.50
28
3.00

2.50

26
2.50

Control

NAFLD

Control

NAFLD

2.00

Control

Female

NAFLD

Male

Fig. 1. Clinical and metabolic variables adjusted by gender and NAFLD condition in Mexican children.
On X axis NAFLD condition is expressed. The values on Y axis express the estimated marginal means.
NAFLD: non-alcoholic fatty liver disease; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; WC: waist circumference; Chol.: cholesterol;
ALT: alanine aminotransferase; AST: aspartate aminotransferase; HOMA-IR: homeostatic model assessment – insulin resistance; VAI: visceral adiposity index.
Female:
; Male:
.

with NAFLD, we found a signiﬁcant AUC value for ALT, AST, WC,
HOMA-IR, triglycerides, and VAI values. Based on these results, and
by calculating the Youden index, we obtained the cut-off points for
these variables in males and females. In females, the optimal cut-off
points were as follows: ALT, 28.5 U/L (sensitivity 100%, speciﬁcity 89.2%); AST, 27.5 U/L (sensitivity 90.90%, speciﬁcity 62.20%);
WC, 79.5 cm (sensitivity 90.90%, speciﬁcity 64.90%); HOMA-IR,
2.08 (sensitivity 100%, speciﬁcity 44.6%); triglycerides, 128 mg/dL

(sensitivity 81.8%, speciﬁcity 69%); and VAI score, 2.33 (sensitivity
100%, speciﬁcity 63.5%).
In male patients, the only signiﬁcant AUC value was found for
ALT concentrations, and the cut-off point was 27.5 U/L (sensitivity
82.60%, speciﬁcity 80.60%; Fig. 2).
The presence of metabolic syndrome (MS) in females with and
without NAFLD was statistically signiﬁcant, as shown by Fisher’s
exact test (OR = 9.019; 95%CI = 2.30–35.30; p = 0.002). However, in
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Table 2
Logistic regression predicting likelihood of NAFLD in Mexican children based on BMI, ALT, WC by gender and triglycerides by gender.
Variable

B

SE

p

OR

BMI (percentile)
ALT (IU/L)
WC by gender
Triglycerides by gender

0.148
0.100
0.014
−0.008

0.094
0.020
0.013
0.006

0.116
<0.001
0.281
0.230

1.159
1.106
1.014
0.992

95%CI
Lower bound

Upper bound

0.964
1.062
0.988
0.980

1.394
1.151
1.041
1.005

NAFLD: non-alcoholic fatty liver disease; BMI: body mass index; ALT: alanine aminotransferase; AST: aspartate aminotransferase; WC: waist circumference; SE: standard
error; OR: Odds Ratio; CI: conﬁdence interval. Bold values are p values < 0.05.

Female

Male

A

B

1.0

1.0

0.8

Sensitivity

Sensitivity

0.8

0.6

0.4

0.6

0.4

0.2

0.2

0.0
0.0

0.2

0.4

0.6

1.0

0.8

0.0
0.0

0.2

1 - Specificity

0.4

0.6

0.8

1.0

1 - Specificity

Variables

AUC

SE

p

95% CI

Variables

AUC

SE

p

95% CI

ALT
VAI
AST
Triglycerides
WC
HOMA-IR

0.949
0.856
0.828
0.822
0.791
0.757

0.023
0.046
0.061
0.056
0.055
0.074

<0.001*
<0.001*
<0.001*
0.001*
0.002*
0.006*

0.904 – 0.994
0.766 – 0.947
0.709 – 0.947
0.713 – 0.932
0.683 – 0.898
0.612 – 0.901

ALT
VAI
AST
Triglycerides
WC
HOMA-IR

0.877
0.607
0.693
0.588
0.658
0.635

0.045
0.062
0.065
0.064
0.067
0.057

0.001*
0.124
0.006*
0.205
0.023*
0.053

0.787 – 0.964
0.485 – 0.729
0.566 – 0.819
0.463 – 0.713
0.528 – 0.788
0.523 – 0.746

ALT

; VAI

; AST

; Triglycerides

; WC

; HOMA-IR

Fig. 2. ROC curves for NAFLD by gender and ALT, AST, WC, VAI, HOMA-IR and triglycerides.
(A) Figure and table for female ROC curve. (B) Figure and table for male ROC curve.
NAFLD: non-alcoholic fatty liver disease; ALT: alanine aminotransferase; AST: aspartate aminotransferase; WC: waist circumference; VAI: visceral adiposity index; HOMA-IR:
homeostatic model assessment – insulin resistance; AUC: area under curve; SE: standard error; CI: conﬁdence interval; *p < 0.05.
; VAI:
; AST:
; triglycerides:
; WC:
; HOMA-IR:
.
ALT:

males with and without NAFLD, there was no signiﬁcant difference
(OR = 1.125; 95%CI = 0.36–3.51; p = 0.84).

4. Discussion
Our study results revealed gender-speciﬁc differences in
metabolic and anthropometric variables related to NAFLD. Moreover, we found evidence that the variables that were positively
associated with insulin resistance, such as insulinemia, HOMA-IR,
triglyceride concentration, and VAI scores, were also associated
with NAFLD in a gender-speciﬁc manner. For example, VAI, HOMAIR, and triglycerides were signiﬁcantly higher in female patients
with NAFLD compared to males. However, in the regression analysis, the only variable that signiﬁcantly predicted the presence of
NAFLD was ALT, which increased the risk of NAFLD by 10% for each
unit increment for both genders.
Mexico currently has one of the highest proportions people with obesity, and consistent with the prevalence of NAFLD,
the frequency of NAFLD in our obesity group was 29.46%. The

development of NAFLD requires a complex interaction of multifactorial features such as genetic susceptibility and environmental
factors. Ramos-López et al. analyzed the pattern of dietary intake
in a Mexican population with and without liver disease, and they
found that both have a diet high in fat and cholesterol that lacks
polyunsaturated fatty acids and some micronutrients with antioxidant properties that have been associated with the development
of liver damage in the general population. The previous statements
could explain the relationship between pediatric patients and the
development of NAFLD through the inﬂuence of genetic variants of
risk, a sedentary lifestyle, and the Mexican obesogenic diet [26].
In our study, the frequency of NAFLD by gender was higher in
boys compared to girls, with a 2:1 ratio. Previous studies that were
included in an epidemiological meta-analysis of NAFLD showed
results similar to ours. Although the diagnostic methodologies used
in the studies included in this meta-analysis were heterogeneous,
the most frequently used method for diagnosing NAFLD was ultrasonography [3,11,27].
NAFLD is associated with various anthropometric and metabolic
factors, such as high BMI, ethnic group (with a higher prevalence

698

E. Villanueva-Ortega et al. / Annals of Hepatology 18 (2019) 693–700

in Asian and Hispanic patients), male gender, insulin resistance,
and dyslipidemia. BMI has also been related to increased visceral
and profound subcutaneous adiposity, which are also considered
to be risk factors for NAFLD [28]. In our study, univariate analyses
performed by gender and the presence of NAFLD showed that in
males, the only variables that were signiﬁcantly related to NAFLD
were ALT and those that indirectly reﬂect visceral adiposity (BMI
and WC). However, in females, NAFLD was also associated with a
higher BMI, WC, and ALT, as well as higher insulin, HOMA-IR, and
VAI. Although in previous studies the variables involved in NAFLD
and insulin resistance are frequently reported, we found that there
is a gender-speciﬁc association between these variables and the
female population [2,6,7].
Our results also showed a signiﬁcant association between
NAFLD and the BMI-Pc, WC, HDL-cholesterol, and ALT concentration, with no differences observed between the genders. This
ﬁnding is in accordance with that of Lonardo et al. and Singh et al.,
who reported that BMI, WC, waist-to-height ratio, and waist-tohip ratio are gender-independent predicting factors for NAFLD in
adults [29,30].
ROC curve discrimination analysis by gender showed a signiﬁcant association between NAFLD and AST, ALT, triglycerides,
HOMA-IR, insulin, and VAI only in girls. In boys, the only variable
that behaved as a possible diagnostic biomarker was ALT, conﬁrming the gender-speciﬁc behavior. The means for ALT in both genders
from our study are aligned with the cut-off points that are recommended by the SAFETY study and the Council for the Treatment of
Child Obesity published by the Endocrine Society [18,31].
In the last two decades, researchers worldwide have described
NAFLD as a condition with sexual dimorphism. Given the complex
multifactorial pathophysiology of NAFLD, research on the sexual
dimorphism inherent to this disease may lead us to a better understanding of the pathophysiological processes that are involved
[11,29].
Women tend to have more subcutaneous adipose tissue and
higher leptin levels, which, combined with estrogen production,
protects them from the accumulation of fatty tissue in the visceral compartment. In contrast, the distribution of adipose tissue
in males is primarily visceral, a condition that is associated with
insulin resistance and a greater inﬂux of free fatty acids into the
portal venous system, thereby promoting NAFLD [10,11,32]. In our
study, we did not observe an association between NAFLD and any
of the factors related to insulin resistance in boys.
The inﬂuence of sex steroids on metabolic disturbances remains
an unanswered question because hyperandrogenic women as well
as men with androgen deﬁciency tend to develop abdominal obesity, insulin resistance, type 2 diabetes, and NAFLD, and they have
a higher cardiovascular risk [33].
Moreover, women with polycystic ovarian syndrome (PCOS)
have an increased prevalence of NAFLD compared to age and BMIpaired controls (OR = 2.54; 95%CI = 2.19–2.95), and NAFLD-PCOS
women have an androgen bioavailability that increases independently of BMI and insulin resistance [34–36]. Conversely, androgen
deﬁciency in men has been related to NAFLD, independent of other
known risk factors such as insulin resistance and visceral adiposity [37]. These studies show that female androgen excess and male
androgen deﬁciency have similar metabolic phenotypes, showing
the complexity of androgens’ role in metabolism.
The variables in our study that were associated with NAFLD in
females are consistent with those observed in previous reports, and
these include insulin resistance, hypertriglyceridemia, and visceral
adiposity (evaluated as VAI and WC in our study). Given that we
did not ﬁnd an association between these variables and NAFLD in
males, we believe that it is possible that the pathophysiological
mechanisms in this population may differ from those involved in
insulin resistance.

For lipid metabolism, studies performed in humans and in
animal models have shown an increased ability in females to
metabolize free fatty acids by lipolysis. However, males can have
prolonged de novo lipogenesis, which may condition them for a
longer period of free fatty acid exposure and their associated damage. These changes could help us to understand why men are more
likely to develop NAFLD [38].
A study performed in the United Kingdom evaluated fatty acid
metabolism according to gender, and it showed that the betaoxidation during fasting in men is less efﬁcient compared to
women, and it also has longer lasting de novo lipogenesis. Both
phenomena may promote esteriﬁcation and storage of free fatty
acids in the liver, and consequently, stimulate the development of
NAFLD in the male population [38].
Experimental models have often shown that androgens and
estrogens are balanced in the modulation of hepatic lipid
metabolism. Zhang et al. suggested that the combined administration of selective androgen and estrogen receptor modulators could
be a potential treatment for patients with NAFLD [39]. Considering
that there is a ﬂuctuation of estrogens or androgens in teenagers,
we attempted to evaluate the effect of these hormones by pubertal
stage; however, there were no differences between pubertal and
prepubertal patients.
The Metabolic syndrome (MS) is a critical factor that is related
to NAFLD, to the extent that NAFLD has been considered by many to
be the hepatic manifestation of this syndrome [40,41]. Concerning
the association of this disorder with MS, it is relevant to say that
in our study, a statistically signiﬁcant relationship was observed
between NAFLD and MS in females but not in males. The frequency
of NAFLD in patients with fewer than three criteria for MS in our
study was 63.9%. These results are clinically relevant, considering
that in children with obesity, the presence of MS is believed to be
the most important risk factor for the development of other comorbidities [42,43]. Our results contribute to the evidence that supports
considering each component of the MS as a risk factor for NAFLD,
particularly hypertriglyceridemia (>110 mg/dL) [44]. Srinivas et al.
studied, from a gender perspective, the association of NAFLD with
MS component risk factors in an urban cohort, and they found that
the components related to this disorder in women were hyperglycemia and hypertriglyceridemia, whereas in men, only BMI was
related (used as a criterion for MS instead of WC) [27]. In our study,
the only risk component among males was the indirect measure
of adiposity (WC), while in females, it was low HDL levels and
hypertriglyceridemia.
This study has some limitations. The most relevant limitation
is that the diagnosis of NAFLD was not performed using the gold
standard (liver biopsy), because of the inherent risks related to
the procedure and ethical issues. We evaluated NAFLD using ultrasonography because of accessibility in our population.
According to our study, ALT, AST, WC, triglycerides, HOMA-IR,
and VAI were only related to NAFLD in the female population. Logistic regression showed that only ALT was predictive of NAFLD in
both genders. The ALT cut-off points for the development of NAFLD
in our study were 28.5 U/L (sensitivity 100%, speciﬁcity 89.2%)
in females and 27.5 U/L (82.60% sensitivity, 80.60% speciﬁcity) in
males. Although ALT was the only predictor for NAFLD in boys, it
does not have the same diagnostic efﬁciency as it does in females.

5. Conclusions
We demonstrated that, although NAFLD is more frequent in
boys, only ALT, and no other clinical or metabolic variables, were
associated with NAFLD in these patients. HOMA-IR, VAI, triglycerides levels, and ALT were associated with NAFLD only in girls.
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The ALT cut-off points for the development of NAFLD in our
study were 28.5 U/L in females and 27.5 U/L in males. Our results
suggest that we may consider each MS criterion individually as a
risk factor for developing NAFLD. Our ﬁndings showed that NAFLD
should be strongly suspected and that patients with obesity should
be intentionally screened for NAFLD, particularly boys.
Further research is required using non-invasive methods and
biomarkers that can help us to predict NAFLD in children and
teenagers.
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